[Induction of remission with TNF-alpha inhibitor in Crohn disease. An analysis of a systematic Cochrane review].
Nielsen
Ole Haagen
OH
Amtssygehuset i Herlev, Medicinsk Gastroenterologisk Afdeling C. ohn@dadlnet.dk
Madsen
Jørgen Rask
JR
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D009363:Neoplasm Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D047889:Receptors, Tumor Necrosis Factor, Type II; D012074:Remission Induction; D053319:Tumor Necrosis Factor Decoy Receptors
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; C402162:CDP 571; D000069285:Infliximab